Related Experiment Videos
Specificity of human complement factor H-related protein test (Bard BTA stat Test)
1Clinic of Surgery, Seinäjoki Central Hospital, Tampere, Finland.
Scandinavian Journal of Urology and Nephrology
|October 9, 1999
Summary
The Bard BTA stat Test, a urine test for bladder cancer, demonstrated 98% specificity in healthy individuals. This rapid, non-invasive diagnostic tool shows promise for bladder cancer screening and monitoring.
Area of Science:
- Urology
- Oncology
- Diagnostic Medicine
Background:
- The Bard BTA stat Test is a novel, rapid, non-invasive qualitative assay.
- It detects bladder tumour-associated antigen (human Complement Factor H-related protein) in urine.
Purpose of the Study:
- To evaluate the diagnostic specificity of the Bard BTA stat Test.
- Assessment was conducted in a healthy, non-patient population.
Main Methods:
- 100 healthy volunteers provided voided urine samples for BTA stat testing.
- Positive results triggered further investigations including imaging and cystoscopy.
- Test-retesting was performed at a three-month follow-up.
Main Results:
- The Bard BTA stat Test exhibited a specificity of 98% in the healthy cohort.
- Two subjects yielded false-positive results; no bladder cancer was detected in these cases.
Conclusions:
- The Bard BTA stat Test demonstrates high specificity, with a low false-positive rate of 2% in healthy individuals.
- These findings support further investigation of the BTA stat Test for bladder cancer diagnosis, screening, and monitoring.